Mount Hope Mining is preparing for a 9 December ASX listing, focusing on copper and gold exploration in the Cobar Basin, with five high-priority targets and a strategy based on recent geological insights.
Copyright 2024 – Finance News Network
11 Mar 2020 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's 1H20 results, including data from its clinical trials, collaborations with major pharma and outlook for the second half.
23 Oct 2019 - Cashwerkz Limited (ASX:CWZ) Executive Director, Craig Swanger talks about the company's platform, the benefit it provides for both banks and investors, FY19 results and outlook.
25 Nov 2020 - Melbana Energy (ASX:MAY) Executive Chairman Andrew Purcell provides an update on its portfolio with particular focus on its onshore Cuban project Block 9, the potential size of the field, drilling program and funding.
01 Aug 2024 - Santana Minerals Limited (ASX:SMI) Executive Director Sam Smith provides an update on the company, discussing the latest high-grade drill results from the Rise and Shine deposit and commenting on the company's recent listing on the New Zealand Stock Exchange.
30 Mar 2020 - XTEK Limited (ASX:XTE) Managing Director Philippe Odouard talks 1H20 results, the company's front-line products for the Australian Defence Force and police forces, US strategy and outlook.
21 Sep 2023 - Brendan Stats - CEO - TMK Energy Limited (ASX:TMK) is a gas exploration company listed on the Australian Stock Exchange. TMK holds a 67% interest in the Gurvantes XXXV Project located in the South Gobi Basin of Mongolia and also holds a 20% interest in the Talisman Depp Project containing the Napoleon Structure located in the Barrow-Dampier Sub-basin.
05 Sep 2024 - IVE Group Limited (ASX:IGL) Managing Director Matt Aitken discusses the company's activities over the past year, touching on key metrics and projects, costs, integration of Ovato, sustainability initiatives, acquisitions of JacPak and Elastic Group, and Lasoo's performance.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.